Swiss National Bank
ZBIO

Swiss National Bank’s Zenas BioPharma ZBIO Stock Holding History

Swiss National Bank’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$618K Hold
31,600
– – ﹤0.01% 2253
2025
Q4 		$1.15M Buy
+31,600
New +$1.04M ﹤0.01% 2116

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Swiss National Bank's ZBIO Position: Q1 2026 in Review

Swiss National Bank held its Zenas BioPharma (ZBIO) position steady in Q1 2026 at 31,600 shares worth $618K. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

Swiss National Bank first reported a position in ZBIO in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.15M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Swiss National Bank held 31,600 shares of Zenas BioPharma worth $618K as of Q1 2026.
  • Swiss National Bank left its Zenas BioPharma share count unchanged in Q1 2026.
  • Zenas BioPharma made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #2253 holding.
  • Swiss National Bank first reported a position in Zenas BioPharma in Q4 2025 and has held it in 2 quarters since.
  • Swiss National Bank's Zenas BioPharma position peaked at $1.15M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.